Publications
53
Citations
373
Est. group size
~34
Recurring co-author estimate
Active years
18
Publishing since 2009
Jinesh Gheeya works in medical oncology, focusing on genomic drivers of cancer and how they inform treatment, particularly in lung, kidney, and other solid tumors. Recent work spans early-phase clinical trials of targeted drug combinations, analysis of DNA-repair gene mutations (such as ATM and PALB2) that affect tumor behavior and drug response, and outcomes of immune checkpoint therapy (a treatment that helps the immune system attack cancer) in patients who experience side effects.
Publication output has grown substantially over the last decade, rising from just a few papers per year before 2020 to a peak of 12-14 per year in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic <i>EGFR</i> -mutated non–small cell lung cancer (NSCLC).
Journal of Clinical Oncology · 2026
- PT2.12.01 Osimertinib Combined With Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients With Metastatic EGFR-Mutated NSCLC
Journal of Thoracic Oncology · 2025
- Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
Clinical Cancer Research · 2024
- Data from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024
- Data from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024
- Supplementary Table S1 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024
- Supplementary S1-S8 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024
- Supplementary Table S1 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024
- Supplementary S1-S8 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024
- Young adults (YA) with non-small cell lung cancer (NSCLC): Snapshot of the oncogenic drivers and immune landscapes.
Journal of Clinical Oncology · 2024
- Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
Journal for ImmunoTherapy of Cancer · 2021
- Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients
Journal of Neuro-Oncology · 2021
- Paraneoplastic Cerebellar Degeneration (PCD) Associated with PCA-1 Antibodies in Established Cancer Patients
Research Square · 2021
- 77P Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors
Annals of Oncology · 2020
- Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy.
Journal of Clinical Oncology · 2020
- Journal of Clinical Oncology×9
- Journal of Thoracic Oncology×4
- Journal of the National Comprehensive Cancer Network×4
- JCO Precision Oncology×3
- Scientific Reports×2
- Kai He
Medicine · The Ohio State University
- Abdul Miah
Medicine · The Ohio State University
- Jing Liang
Medicine · The Ohio State University
- Kevin Ho
Medicine · The Ohio State University
- Yan Han
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile